Effect of amprolium on acute sarcocystosis in experimentally infected calves.
Twelve calves were used to determine whether treatment with amprolium affected the severity of experimental Sarcocystis fusiformis infections. In each of 2 experiments, 2 calves received an oral dose of amprolium at 100 mg/kg of body weight for 30 days, 2 calves were similarly inoculated but received no medication, and 2 calves served as uninoculated, unmedicated controls. Data from overall weight gains, packed cell volume, body temperature, postmortem and histological examinations, and serum enzyme levels indicate that amprolium reduced the severity of experimental sarcocystosis.
D000670:Amprolium / Q000627:therapeutic use*; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001831:Body Temperature; D001835:Body Weight; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy* / Q000473:pathology; D003402:Creatine Kinase / Q000097:blood; D006400:Hematocrit; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D010847:Picolines / Q000031:analogs & derivatives*; D012522:Sarcocystis; D012523:Sarcocystosis / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*
D010847:Picolines; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D003402:Creatine Kinase; D000670:Amprolium